JP2004532896A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004532896A5 JP2004532896A5 JP2003507548A JP2003507548A JP2004532896A5 JP 2004532896 A5 JP2004532896 A5 JP 2004532896A5 JP 2003507548 A JP2003507548 A JP 2003507548A JP 2003507548 A JP2003507548 A JP 2003507548A JP 2004532896 A5 JP2004532896 A5 JP 2004532896A5
- Authority
- JP
- Japan
- Prior art keywords
- leu
- compound
- group
- val
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 42
- 238000000034 method Methods 0.000 claims 34
- 210000001744 T-lymphocyte Anatomy 0.000 claims 12
- 150000001413 amino acids Chemical class 0.000 claims 12
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 10
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims 8
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims 8
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 claims 6
- 125000006728 (C1-C6) alkynyl group Chemical group 0.000 claims 6
- 230000002163 immunogen Effects 0.000 claims 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 5
- 241001465754 Metazoa Species 0.000 claims 5
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 4
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 claims 3
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 claims 3
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 claims 3
- PLOPBXQQPZYQFA-AXPWDRQUSA-N amlintide Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)CSSC1)[C@@H](C)O)C(C)C)C1=CC=CC=C1 PLOPBXQQPZYQFA-AXPWDRQUSA-N 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 241000024188 Andala Species 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 231100000433 cytotoxic Toxicity 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 210000004698 lymphocyte Anatomy 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 101100514845 Arabidopsis thaliana MTV1 gene Proteins 0.000 claims 1
- 229940126062 Compound A Drugs 0.000 claims 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 1
- 241000283984 Rodentia Species 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 238000010171 animal model Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 238000002405 diagnostic procedure Methods 0.000 claims 1
- 210000004153 islets of langerhan Anatomy 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 210000005259 peripheral blood Anatomy 0.000 claims 1
- 239000011886 peripheral blood Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 210000004989 spleen cell Anatomy 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29975401P | 2001-06-22 | 2001-06-22 | |
| PCT/CA2002/000975 WO2003001204A2 (en) | 2001-06-22 | 2002-06-25 | Type 1 diabetes diagnostics and therapeutics |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004532896A JP2004532896A (ja) | 2004-10-28 |
| JP2004532896A5 true JP2004532896A5 (enExample) | 2006-01-05 |
Family
ID=23156146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003507548A Pending JP2004532896A (ja) | 2001-06-22 | 2002-06-25 | I型糖尿病の診断及び治療 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20050129617A1 (enExample) |
| EP (1) | EP1399740A2 (enExample) |
| JP (1) | JP2004532896A (enExample) |
| CA (1) | CA2449990A1 (enExample) |
| WO (1) | WO2003001204A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7479482B2 (en) * | 2001-11-21 | 2009-01-20 | New York University | Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid β, prion protein, amylin, α-synuclein, or polyglutamine repeats for induction of an immune response thereto |
| EP1846438A2 (en) * | 2005-01-31 | 2007-10-24 | Leiden University Medical Center | Methods and means for use in diagnostics and treatment of diabetes |
| DK2131856T3 (da) * | 2007-03-07 | 2014-12-15 | Uti Limited Partnership | Sammensætninger og fremgangsmåder til forebyggelsen og behandlingen af autoimmune tilstande |
| US9511151B2 (en) | 2010-11-12 | 2016-12-06 | Uti Limited Partnership | Compositions and methods for the prevention and treatment of cancer |
| US10988516B2 (en) | 2012-03-26 | 2021-04-27 | Uti Limited Partnership | Methods and compositions for treating inflammation |
| US20140068487A1 (en) * | 2012-09-05 | 2014-03-06 | Roche Diagnostics Operations, Inc. | Computer Implemented Methods For Visualizing Correlations Between Blood Glucose Data And Events And Apparatuses Thereof |
| US9603948B2 (en) | 2012-10-11 | 2017-03-28 | Uti Limited Partnership | Methods and compositions for treating multiple sclerosis and related disorders |
| SG10201912301XA (en) | 2013-11-04 | 2020-02-27 | Uti Lp | Methods and compositions for sustained immunotherapy |
| US8993008B1 (en) | 2013-12-16 | 2015-03-31 | Umm Al-Qura University | Herbal composition for treating diabetes |
| DE102015003676A1 (de) * | 2015-03-20 | 2016-09-22 | Forschungszentrum Jülich GmbH Fachbereich Patente | Spezifisch A-Beta Spezies bindende Peptide für die Therapie und/oder die Diagnose der Alzheimerschen Demenz |
| US12011480B2 (en) | 2015-05-06 | 2024-06-18 | Uti Limited Partnership | Nanoparticle compositions for sustained therapy |
| CN111741746A (zh) | 2017-11-29 | 2020-10-02 | 乌第有限合伙公司 | 治疗自身免疫性疾病的方法 |
| CN108152503A (zh) * | 2017-12-19 | 2018-06-12 | 上海澜帆实业有限公司 | 酶联免疫斑点印迹的自身免疫检测试剂盒及其操作流程 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4554101A (en) * | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US4838852A (en) * | 1987-03-27 | 1989-06-13 | Therakos, Inc. | Active specific immune suppression |
| US6039947A (en) * | 1987-06-24 | 2000-03-21 | Autoimmune, Inc. | Peptides derived from immunodominant epitopes of myelin basic protein |
| US5147289A (en) * | 1990-03-29 | 1992-09-15 | Therakos, Inc | Non-specific immune system enhancement |
| US5858980A (en) * | 1990-03-30 | 1999-01-12 | Autoimmune, Inc. | Peptide fragments of myelin basic protein |
| US5580953A (en) * | 1991-08-14 | 1996-12-03 | Amylin Pharmaceuticals, Inc. | Amylin antagonist peptides and uses therefor |
| US5651993A (en) * | 1992-11-18 | 1997-07-29 | Yale University | Specific immune system modulation |
| US5635363A (en) * | 1995-02-28 | 1997-06-03 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for the detection, quantitation and purification of antigen-specific T cells |
| US6007821A (en) * | 1997-10-16 | 1999-12-28 | Fordham University | Method and compositions for the treatment of autoimmune disease using heat shock proteins |
| EP1094828A4 (en) * | 1998-05-07 | 2005-01-26 | Univ California | USE OF TARGETED, NEGLIGATED TISSUE ANTIGENS TO MODULATE IMMUNE REACTIONS |
| AU7033400A (en) * | 1999-08-30 | 2001-03-26 | Jehad Mikhaiel Charo | Induction of cytotoxic t lymphocyte response by hla class ia restricted epitopesof mycobacterial heat shock protein 65 |
-
2002
- 2002-06-25 EP EP02742604A patent/EP1399740A2/en not_active Withdrawn
- 2002-06-25 WO PCT/CA2002/000975 patent/WO2003001204A2/en not_active Ceased
- 2002-06-25 US US10/481,696 patent/US20050129617A1/en not_active Abandoned
- 2002-06-25 CA CA002449990A patent/CA2449990A1/en not_active Abandoned
- 2002-06-25 JP JP2003507548A patent/JP2004532896A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004532896A5 (enExample) | ||
| Robbins et al. | Antibodies to covalent aggregates of insulin in blood of insulin-using diabetic patients | |
| Martin et al. | T cell recognition of haptens, a molecular view | |
| AU766545B2 (en) | Novel anti-diabetic peptides | |
| Putnam et al. | Structure and evolution of kappa and lambda light chains | |
| US5807552A (en) | Compositions for conferring immunogenicity to a substance and uses thereof | |
| CA2516702A1 (en) | Modified t cell receptor linked by disulphide bond between constant domain cysteine residues | |
| JP2002206000A5 (enExample) | ||
| RU2020136305A (ru) | Производные gip и пути их применения | |
| TW200835513A (en) | HLA-A* 1101-restricted WT1 peptide and pharmaceutical composition comprising the same | |
| Low et al. | Structure, function, and evolutionary relationships of Fc domains of human immunoglobulins A, G, M, and E | |
| Chance | Amino acid sequences of proinsulins and intermediates | |
| EA003944B1 (ru) | Способы лечения диабета с помощью пептидных аналогов инсулина | |
| EA012507B1 (ru) | Высокоаффинные мелан-а т-клеточные рецепторы | |
| Rutishauser et al. | Amino acid sequence of the Fc region of a human gamma G-immunoglobulin. | |
| KR20090059152A (ko) | 쿠프레독신으로 암을 예방하는 조성물과 방법 | |
| CZ292454B6 (cs) | Peptid schopný neutralizovat nebo modulovat produkci anti-myelinového bazického proteinu a jeho použití při léčbě sklerózy multiplex | |
| Bierwagen et al. | Strong interactions between Salp15 homologues from the tick I. ricinus and distinct types of the outer surface OspC protein from Borrelia | |
| EP0815136B1 (en) | Immunoreactive and immunotherapeutic molecules which interact in subjects with insulin-dependent diabetes mellitus (iddm) | |
| JP2006515744A5 (enExample) | ||
| Joshi et al. | Flexibility in MHC and TCR recognition: degenerate specificity at the T cell level in the recognition of promiscuous Th epitopes exhibiting no primary sequence homology | |
| AU2001285427B2 (en) | Stress proteins and peptides and methods of use thereof | |
| Chen et al. | Identification and characterization of a T cell-inducing epitope of bovine ribonuclease that can be restricted by multiple class II molecules | |
| CN111454371A (zh) | PDL1-pHLIP、制备方法及其在治疗自身免疫病中的应用 | |
| Hamada et al. | Molecular interactions of surface protein peptides of Streptococcus gordonii with human salivary components |